AbbVie Inc. reported second-quarter 2025 revenue of $15.42 billion, topping the $15 billion expected by analysts, while adjusted earnings rose 12 percent year on year to $2.97 a share, beating the $2.88 consensus. On a GAAP basis, diluted EPS fell to $0.52, reflecting a $0.42-per-share charge tied to acquired R&D and milestone payments. Sales of newer immunology drugs continued to accelerate. Skyrizi generated $4.42 billion in global revenue, up 62 percent from a year earlier, and Rinvoq brought in $2.03 billion, a 42 percent increase. Those gains helped offset a 58 percent slide in Humira revenue to $1.18 billion as biosimilar competition intensified. Oncology therapy Imbruvica contributed $754 million, modestly above estimates. Buoyed by the strength of its growth portfolio, the company lifted its full-year 2025 adjusted earnings forecast to a range of $11.88 to $12.08 a share, up from $11.67 to $11.87 previously. The new outlook already factors in a $0.55-per-share hit from in-process R&D expenses booked in the first half. The earnings beat and higher guidance sent AbbVie shares up roughly 3.5 percent in pre-market trading on Thursday, positioning the drugmaker to extend gains as investors gain confidence that Skyrizi and Rinvoq can replace lost Humira revenue ahead of schedule.